Neuen et al. additionally described the benefits of combination therapy with GLP-1 RAs, SGLT2is, and the nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone in patients with albuminuria, T2DM, and cardiovascular disease. This evidence concerns the gene GCG and type 2 diabetes mellitus.